2025-09-09 - Analysis Report
Okay, let's break down the analysis of Eli Lilly (LLY) based on the provided data.

**Report on Eli Lilly and Co (LLY)**

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures, and markets pharmaceutical products.

**1. Performance vs. S&P 500 (VOO)**

*   **Cumulative Return (LLY):** 217.63%
*   **Cumulative Return (VOO):** 101.31%
*   **Absolute Deviation:** 116.3
*   **Relative Deviation:** 42.4 (Indicates LLY's outperformance is in the upper range of its historical deviation from VOO)

**Analysis:** LLY has significantly outperformed the S&P 500 over the covered period. The relative deviation suggests that this outperformance is substantial compared to LLY's historical performance relative to the index.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD     | Alpha   | Beta  | Cap(B) |
|------------|---------|---------|---------|-------|--------|
| 2015-2017  | 10.0%   | 56.3%   | -19.0%  | 0.0   | 76.9   |
| 2016-2018  | 39.0%   | 58.6%   | 21.0%   | -0.1  | 105.4  |
| 2017-2019  | 50.0%   | 58.6%   | 20.0%   | 0.3   | 119.7  |
| 2018-2020  | 52.0%   | 58.6%   | 33.0%   | 0.1   | 153.7  |
| 2019-2021  | 106.0%  | 60.6%   | 57.0%   | 0.2   | 251.5  |
| 2020-2022  | 98.0%   | 64.8%   | 96.0%   | 0.2   | 333.1  |
| 2021-2023  | 133.0%  | 64.8%   | 115.0%  | 0.3   | 530.8  |
| 2022-2024  | 150.0%  | 72.2%   | 124.0%  | 0.2   | 702.9  |
| 2023-2025  | 71.0%   | 76.8%   | 17.0%   | 0.2   | 662.2  |

**Analysis:**

*   **CAGR:**  High CAGRs in recent periods indicate strong growth.
*   **MDD:**  Maximum Drawdown figures are substantial, reflecting market volatility and the inherent risks in pharmaceutical investments.
*   **Alpha:**  Strong and increasing positive alpha suggests LLY is generating returns independent of the market.
*   **Beta:**  Low beta values indicate that LLY's price is not as sensitive to market movements as the S&P 500.
*   **Cap(B):** Market capitalization has grown significantly, reflecting investor confidence and company growth.

**2. Recent Price Action**

*   **Current Price:** 727.2100219726562
*   **Last Market Data:** {'price': 738.64, 'previousClose': 727.21, 'change': 1.57} (Indicates a gap up and positive movement)
*   **5-day Moving Average:** 735.108
*   **20-day Moving Average:** 702.384
*   **60-day Moving Average:** 753.1298

**Analysis:**

*   The price gapped up and moved up a bit (1.57).
*   The price is trading below its 5-day and 60-day moving averages but above its 20-day moving average. This suggests some short-term volatility but an overall upward trend in the medium term.

**3. Technical Indicators & Expected Return**

*   **Market Risk Indicator (MRI):** 0.33 (Low Risk)
*   **RSI:** 62.42 (Approaching overbought territory, but not yet extreme)
*   **PPO:** 0.8655 (Positive, indicating an upward trend)
*   **Hybrid Signal:** Buy 80% (Suggests a buying opportunity with caution due to the MRI)
*   **20-day Relative Deviation Change:** -0.7 (Short-term decline in relative performance)
*   **Expected Return:** 219.7% (Significant potential outperformance vs. S&P 500 over the long term)

**Analysis:** The technical indicators suggest a potentially favorable, but not risk-free, investment opportunity. The MRI indicates low market risk, which is positive. However, the RSI approaching overbought territory and the recent decline in relative deviation warrant some caution. The large expected return indicates that the AI model expects LLY to strongly outperform the S\&P 500 in the future.

**4. Recent News & Significant Events**

*   **Strategic Investment:** Immix Biopharma receiving investment (Indirectly positive for the sector).
*   **WHO and GLP-1RAs:** WHO adding GLP-1RAs to essential medicines list (Potentially very positive for LLY, given its diabetes and weight loss drug portfolio).
*   **Jaypirca Phase 3 Results:** Positive results for Jaypirca in CLL (Positive for LLY's oncology pipeline).
*   **Jim Cramer Recommendation:** Cramer recommending LLY over Viking Therapeutics (Positive sentiment).
*   **Orforglipron Results:** Positive Phase 3 results for Orforglipron at Chugai (Competition in the GLP-1 space).

**Analysis:** The news flow is overwhelmingly positive, especially the WHO inclusion of GLP-1RAs and the positive trial results for Jaypirca. While competition is emerging, the overall news supports a bullish outlook for LLY.

**4-2. Analyst Opinions**

*   **Consensus:** Buy
*   **Mean Rating:** 1.68 (~Buy)
*   **Opinions:** 26
*   **Target Price (avg/high/low):** 891.62 / 1190.00 / 650.00

**Analysis:** Analyst ratings are strongly positive, and the average target price suggests significant upside potential from the current price.

**5. Recent Earnings Analysis**

| 날짜       | EPS    | 매출       |
|------------|--------|------------|
| 2025-08-07 | 6.3    | 15.56 B$   |
| 2025-05-01 | 3.07   | 12.73 B$   |
| 2024-10-30 | 1.08   | 11.44 B$   |
| 2024-08-08 | 3.29   | 11.30 B$   |
| 2025-08-07 | 3.29   | 11.30 B$   |

**Analysis:** Earnings Per Share (EPS) and revenue generally show an upward trend, with a particularly strong recent quarter (2025-08-07).

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-06-30   | $15.56B    | 84.27%        |
| 2025-03-31   | $12.73B    | 82.53%        |
| 2024-12-31   | $13.53B    | 82.24%        |
| 2024-09-30   | $11.44B    | 81.02%        |
| 2024-06-30   | $11.30B    | 80.80%        |

**Capital and Profitability:**

| Quarter      | Equity     | ROE       |
|--------------|------------|-----------|
| 2025-06-30   | $18.27B    | 30.98%    |
| 2025-03-31   | $15.76B    | 17.50%    |
| 2024-12-31   | $14.19B    | 31.07%    |
| 2024-09-30   | $14.24B    | 6.81%     |
| 2024-06-30   | $13.56B    | 21.88%    |

**Analysis:** Revenue, profit margin, equity, and Return on Equity (ROE) have all generally increased over the reported period, indicating improving financial performance.  The profit margins are exceptionally high, suggesting strong pricing power and efficient operations.

**7. 종합 Analysis**

LLY exhibits strong growth characteristics, driven by increasing revenues, high profit margins, and positive developments in its drug pipeline (especially in GLP-1RAs and oncology). Analyst sentiment is bullish, and the technical indicators, while suggesting some short-term caution, support a positive longer-term outlook. The MRI indicating low market risk adds to the positive picture. Overall, LLY appears to be a compelling investment opportunity, but as with any stock, potential investors should consider their own risk tolerance and conduct thorough due diligence.
